Advertisement

Conflict of Interest Policy

*Please note that the 2005 ASCO COI Policy is still in effect for the 2014 Annual Meeting.  For questions regarding the 2013 ASCO Policy for Relationships with Companies, please see the FAQ page.

In compliance with standards established by the ASCO Conflict of Interest Policy (J Clin Oncol. 2006; 24[3]:519–521) and the Accreditation Council for Continuing Medical Information (ACCME), ASCO strives to promote balance, independence, objectivity, and scientific rigor through disclosure of financial and other interests, and identification and management of potential conflicts. According to the Society’s Conflict of Interest Policy, the following financial and other relationships must be disclosed: employment or leadership position, advisory role, stock ownership, honoraria, research funding, expert testimony, and other remuneration (J Clin Oncol. 2006;24[3]:520).

The ASCO Conflict of Interest Policy requirements apply to all abstract authors. It is the responsibility of the first author to obtain disclosure information from all coauthors and to provide all disclosure of such interests and relationships through the Abstract Submitter program. Copies of the Disclosure Forms can be sent to coauthors for completion and return before submission of the abstract.

Per the ASCO Conflict of Interest Policy Implementation Plan for CME Activities, all oral abstract presenters will be subject to the same disclosure review and management strategies as faculty who participate in ASCO CME activities.

For clinical trials that began accrual on or after April 29, 2004, the Conflict of Interest Policy places some restrictions on the financial relationships between a trial’s principal investigator (PI) and the trial’s company sponsor (J Clin Oncol. 2006;24[3]:521). If a PI holds any restricted relationships, his or her abstract may be ineligible for placement in the 2014 Annual Meeting unless the Ethics Committee grants an exception. Exceptions are generally not granted for PIs who have employment relationships with their trial’s company sponsor or stock in the company sponsor. Abstracts that receive exceptions will be subject to additional management strategies, including but not limited to additional peer review, advance slide review, and session audits.

ASCO will collect information on accrual initiation date, financial relationships of the principal investigator, and National Institutes of Health (NIH) funding upon abstract submission. NIH-funded trials are exempt from the PI restrictions in the Conflict of Interest.

For more information on the ASCO Conflict of Interest Policy, the Conflict of Interest Policy Implementation Plan for CME Activities, and the restrictions on PIs, please visit asco.org/rwc.

Additional Questions for Clinical Trial Abstracts That Do Not Identify a Principal Investigator

ASCO's Conflict of Interest Policy identifies the PI of a clinical trial as "the individual with primary responsibility for the development of the protocol, the conduct of the trial, and the interpretation and dissemination of the trial data." Generally, it is expected that these responsibilities will rest with a single individual designated as the PI and having the unique leadership responsibilities described in the policy.

Identifying a PI is not required for abstract submission. However, first authors of clinical trial abstracts that do not identify a PI will be asked to respond to additional questions about the individual(s) who completed the responsibilities assigned to the PI under ASCO’s Conflict of Interest Policy.